Developing new drugs to treat skin injuries from arsenic exposure
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
This study is looking at how certain chemicals from arsenic, which have been used in warfare, can harm the skin, and it aims to find better treatments for people who might be affected by these harmful substances.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11115192 on NIH RePORTER |
What this research studies
This research focuses on understanding how arsenic-based chemicals, which have been used in warfare, cause severe skin damage. By using animal models that mimic human skin reactions, the team aims to identify the biological processes that lead to inflammation and pain from arsenic exposure. The goal is to develop effective treatments that can reduce the harmful effects of these toxic agents on the skin. Patients who may be exposed to arsenic through various means could benefit from the findings of this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced skin injuries due to arsenic exposure, whether from chemical warfare or accidental exposure.
Not a fit: Patients who have not been exposed to arsenic or do not have skin injuries related to arsenic exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly alleviate skin injuries caused by arsenic exposure.
How similar studies have performed: Previous research has successfully identified biological mechanisms related to arsenic exposure, suggesting that this approach has potential for meaningful advancements.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Athar, Mohammad — University of Alabama at Birmingham
- Study coordinator: Athar, Mohammad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.